Opexa shares skyrocket on Ph3 MS progress

Shares of Opexa Therapeutics shot up more than 60 percent this morning--taking a big gain on a relatively modest step forward on its new MS therapy Tovaxin. The developer says that it successfully completed two discussions with regulators on its late-stage study of Tovaxin. "We are very pleased with the outcome of our two recent FDA meetings regarding Tovaxin, the first ever personalized T-cell therapy for MS patients, as we believe we now have a well defined path forward for Phase 3 clinical studies," commented CEO Neil Warma. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.